Trevena Announces Advancement of TRV045 Into Clinical Development for Diabetic Neuropathic Pain
December 13, 2021 07:00 ET
|
Trevena Inc.
3-part randomized, double-blind, placebo-controlled Phase 1 study will evaluate TRV045 safety, tolerability, and PK in healthy volunteers Enrollment expected to start in early Q1 2022 CHESTERBROOK,...
Trevena Reports Third Quarter 2021 Results
November 15, 2021 07:00 ET
|
Trevena Inc.
-- Advanced OLINVYK commercial launch with expanded field medical team and additional target markets Announced new OLINVYK cognitive function study vs. IV morphine, enrollment expected...
Trevena Adds Seasoned Biopharma Commercial Executive to Senior Leadership Team
November 11, 2021 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena to Release Third Quarter 2021 Financial Results on November 15th, 2021
November 08, 2021 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Two OLINVYK® Presentations at ANESTHESIOLOGY® 2021
October 13, 2021 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Results of TRV027 Proof-of-Concept Study in COVID-19 Patients
September 30, 2021 07:00 ET
|
Trevena Inc.
-- 92% probability that TRV027 has a potential beneficial impact on primary endpoint of D-dimer levels, a biomarker associated with critical illness and mortality ~12 days lower average...
Trevena to Present at the Oppenheimer 2021 Fall Healthcare Life Sciences & MedTech Summit
September 17, 2021 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Two OLINVYK® Abstracts Highlighting Safety Data Accepted at ANESTHESIOLOGY® 2021
August 30, 2021 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Penn., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Wake Forest Baptist Health Joining OLINVYK® Clinical Outcomes Study
August 25, 2021 07:00 ET
|
Trevena Inc.
-- Study is being led by Cleveland Clinic; designed to evaluate potential benefit of OLINVYK on respiratory, GI, and cognitive function outcomes in postoperative patients Patient enrollment...